Study Details

PROTOCOL SUMMARY

The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.

Participation Requirements

Age

2 Years - 17 Years

Sex

ALL

Healthy Volunteers

Medical Condition

Chronic Hepatitis B

Gender

N/A

Date

November 2016 - December 2025

Study Type

INTERVENTIONAL

Study Phase

PHASE2

Product

TAF, Placebo

Eligibility Information

Inclusion Criteria

Males and non-pregnant, non-lactating females
Weight at screening as follows:
Cohort 1 = ≥ 35 kg (≥ 77 lbs)
Cohort 2 Group 1 = ≥ 25 kg (≥ 55 lbs)
Cohort 2 Group 2 = ≥ 14 kg to < 25 kg (≥ 30 lbs to <55 lbs)
Cohort 2 Group 3 = ≥ 10 kg to < 14 kg (≥ 22 lbs to < 30 lbs) or
14 kg to < 25 kg (≥ 30 lbs to < 55 lbs)
Willing and able to provide written informed consent/assent (child and parent/legal guardian)
Documented evidence of CHB (eg, HBsAg-positive for ≥ 6 months)
HBeAg-positive, or HBeAg-negative, chronic HBV infection with all of the following:
Screening HBV DNA ≥ 2 × 10^4 IU/mL
Screening serum ALT > 45 U/L (> 1.5 × ULN: 30 U/L) and ≤ 10 × ULN (by central laboratory range)
Treatment-naive or treatment-experienced will be eligible for enrollment.
Estimated creatinine clearance (CLCr) ≥ 80 mL/min/1.73m^2 (using the Schwartz formula)
Normal ECG

Exclusion Criteria

Females who are pregnant or breastfeeding
Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study.
Coinfection with hepatitis C virus (HCV), HIV, or hepatitis D virus (HDV)
Evidence of hepatocellular carcinoma (Note: if screening alpha-fetoprotein (AFP) is < 50 ng/mL no imaging study is needed; however, if the screening AFP is > 50 ng/mL an imaging study is required)
Any history of, or current evidence of, clinical hepatic decompensation
Abnormal hematological and biochemical parameters
Chronic liver disease of non-HBV etiology (e.g., hemochromatosis, alpha-1 antitrypsin deficiency, cholangitis)
Received solid organ or bone marrow transplant
Currently receiving therapy with immunomodulators (eg, corticosteroids), or immunosuppressants
Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the Investigator
Malignancy within the 5 years prior to screening. Individuals under evaluation for possible malignancy are not eligible.
Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Locations

Locations (39)

Children's Hospital of Los Angeles

Los Angeles, California, United States, 90027

Rady Childrens Hospital

San Diego, California, United States, 92123

University of California, San Francisco (UCSF)

San Francisco, California, United States, 94158

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

Indiana University School of Medicine

Indianapolis, Indiana, United States, 46202

Johns Hopkins University

Baltimore, Maryland, United States, 21287

Children's Mercy Hospital

Kansas City, Missouri, United States, 64108

The Children's Hospital at Montefiore

Bronx, New York, United States, 10467

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Nationwide Children's Hospital

Columbus, Ohio, United States, 43205

Monroe Carell Jr. Children's Hospital at Vanderbilt

Nashville, Tennessee, United States, 37232

Cook Children's Medical Center

Fort Worth, Texas, United States, 76104

Texas Children's Hospital - Main Hospital

Houston, Texas, United States, 77030

American Research Corporation at Texas Liver Institute

San Antonio, Texas, United States, 78215

Seattle Children's Hospital

Seattle, Washington, United States, 98105

Cliniques Universitaires Saint-LUC UCL

Brussels, Belgium, 1200

Prince of Wales Hospital

Shatin, Hong Kong

Institute of Post Graduation Medical Education & Research

Kolkata, India, 700020

M. V Hospital and Research Center

Lucknow, India, 226003

Seth GS Medical College and KEM Hospital

Mumbai, India, 400012

LTMMC & LTMG Hospital

Mumbai, India, 400022

Khalatkar Hospital

Nagpur, India, 440009

All India Institute of Medical Sciences

New Delhi, India, 110029

SIDS Hospital and Research Centre

Surat, India, 395002

Samvedna Hospital

Varanasi, India, 221005

Kyungpook National University Hospital

Daegu, Korea, Republic of, 41944

Asan Medical Center

Seoul, Korea, Republic of, 5505

Samsung Medical Center

Seoul, Korea, Republic of, 6351

Spitalul Grigore Alexandrescu-Sectia Pediatrie III

Bucharest, Romania, 11743

Institutul National de Boli Infectioase "Prof.Dr. Matei Bals"

Bucharest, Romania, 21105

Federal Research Centre of Nutrition, Biotechnology and Food Safety

Moscow, Russian Federation, 115446

Federal State-Financed Institution Pediatric Research and Clinical Center for Infectious Diseases

Saint-Petersburg, Russian Federation, 197022

Republican Clinical Hospital of Infectious Diseases named after A.F. Agafonov

Tatarstan, Russian Federation, 420110

Limited Medical Company Hepatolog

Tolyatti, Russian Federation, 445009

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, Taiwan, 807

Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital

Kaohsiung, Taiwan, 83301

National Cheng Kung University Hospital

Tainan, Taiwan, 704

National Taiwan University Hospital

Taipei, Taiwan, 100

Chang Gung Medical Foundation, Chang Gung Memorial Hospital, Linkou

Taoyuan, Taiwan, 33305

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

OVERVIEW